Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro.
ACE2
Astemizole
Drug re-use
SARS-COV-2
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
11
10
2020
revised:
26
03
2021
accepted:
08
04
2021
pubmed:
2
5
2021
medline:
22
6
2021
entrez:
1
5
2021
Statut:
ppublish
Résumé
Since the beginning of December 2019, a novel Coronavirus severe respiratory disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which also been termed 2019-new CoV (2019-nCoV), has continued to spread worldwide. As of August 27, 2020, a total of 24,232,429 people have been infected and 826,518 people have died. In our study, we found that astemizole can antagonize ACE2 and inhibit the entry of SARS-COV-2 spike pseudovirus into ACE2-expressed HEK293T cells (ACE2hi cells). We analysied the binding character of astemizole to ACE2 by molecular docking and surface plasmon resonance (SPR) assays and molecule docking, SARS-COV-2 spike pseudotype virus was also taken to investigate the suppression viropexis effect of astemizole. The results showed that astemizole can bind to the ACE2 receptor and inhibit the invasion of SARS-COV-2 Spike pseudoviruses. Thus astemizole represent potential drug candidates that can be re-used in anti-coronavirus therapies.
Identifiants
pubmed: 33932547
pii: S0882-4010(21)00201-1
doi: 10.1016/j.micpath.2021.104929
pmc: PMC8081582
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Spike Glycoprotein, Coronavirus
0
Astemizole
7HU6337315
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104929Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.
Références
Circ Res. 2020 May 8;126(10):1456-1474
pubmed: 32264791
J Virol. 2012 Mar;86(6):3284-92
pubmed: 22238307
J Pharm Biomed Anal. 2015 Oct 10;114:121-6
pubmed: 26037160
Bioorg Med Chem. 2012 Nov 1;20(21):6208-36
pubmed: 23031649
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Cardiovasc Res. 2020 Oct 1;116(12):1932-1936
pubmed: 32267499
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Bioorg Med Chem. 2014 Sep 1;22(17):4893-909
pubmed: 25082514
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
In Vivo. 2020 Jun;34(3 Suppl):1597-1602
pubmed: 32503817
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
PLoS One. 2012;7(9):e45063
pubmed: 22984610
F1000Res. 2020 Jan 31;9:72
pubmed: 32117569
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Clin Sci (Lond). 2020 Apr 17;134(7):747-750
pubmed: 32255491
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Clin Pharmacol Ther. 2010 Mar;87(3):356-61
pubmed: 20130565
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
Monaldi Arch Chest Dis. 2020 May 14;90(2):
pubmed: 32498503
Br J Pharmacol. 2018 Jan;175(2):168-180
pubmed: 28369768
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Eur J Intern Med. 2020 Jun;76:14-20
pubmed: 32336612